De novo sequencing of MS/MS spectra by Allmer, Jens
Algorithms for the De Novo Sequencing of Peptides 
from Tandem Mass Spectra 
Jens Allmer 
Molecular Biology and Genetics, Izmir Institute of Technology, Urla, Izmir, 35430, 
Turkey  
Phone: 00902327507517, Fax: 00902327507509, Email: jens@allmer.de 
 
 
Abstract 
Proteomics is the study of the proteins, their time and location dependent expression 
profiles as well as their modifications and interactions. Mass spectrometry is useful to 
investigate many of the questions asked in proteomics. Typically database search 
methods are employed to identify proteins from complex mixtures. However, often 
databases are not available or despite their availability some sequences are not readily 
found therein. To overcome this problem de novo sequencing can be used to directly 
assign a peptide sequence to an MS/MS spectrum. Many algorithms have been proposed 
for de novo sequencing and a selection of them is detailed in this review. Although a 
standard accuracy measure has not been agreed upon in the field, relative algorithm 
performance is discussed. The current state of the de novo sequencing is assessed 
thereafter and finally, examples are used to construct possible future perspectives of the 
field. 
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Introduction 
Proteomics aims to investigate the complement of a genome, the proteome. The proteome 
is the entirety of proteins that can be expressed by a genome, including alternatively 
spliced and modified products. Today mass spectrometry (MS) is the tool of choice for 
protein identification and quantification [1]. For many forms of quantitation an initial 
identification of peptides and proteins is necessary; see for example [2]. Therefore, the 
correct assignment of an amino acid sequence to each tandem MS (MS/MS, MS
2
) 
spectrum is crucial for many scenarios in mass spectrometry based proteomics. There are 
basically two methods to assign a sequence to MS/MS spectra. One widespread method is 
dependent on the availability of sequences in a database. Simplified, all sequences in the 
database can be scored against the spectrum and the best scoring sequence is then 
accepted as the precursor of the MS/MS spectrum. Sequest [3], Mascot [4], Omssa [5], 
and X!Tandem [6] are just a few examples of the many algorithms available in the field 
of database searching. The downside of database searching is that sequences are not 
always in the database [7]; even in the six frame translation of a genomic database they 
may not be present. Alternative splice forms, short proteins, wrong (even if just slightly) 
gene predictions, and many other factors prevent the correct assignment of sequence to 
spectrum. This further depends on the complexity of the sample, the mass spectrometer 
used, and the settings for false discovery rate. Unfortunately, some tandem mass spectra 
may fit well to an unrelated sequence in the database and thus lead to false 
identifications. Another big problem is posed by post translational modifications (PTMs) 
of amino acids which shift the mass of the precursor and thus renders an assignment of 
sequence to spectrum impossible, unless the modification is anticipated. Peptidomics is 
an emerging field interested in bioactive peptides which, unlike peptides found in high-
throughput studies, do not result from tryptic cleavage and are usually heavily modified 
and therefore may pose problems to database search algorithms [8]. Similar problems 
apply when the target sequences are antibodies [9], hormones, or toxins. 
De novo sequencing, which aims to assign a sequence to MS/MS spectra without the 
need for a sequence database, is the other method used. Although there is no sequence 
database used in this approach, the search space can be represented in the same way (see 
naïve approach). The theoretical search space for de novo sequencing algorithms 
encompasses the entirety of amino acid sequences that can account for the precursor 
mass, within a certain mass tolerance, dictated by the mass spectrometer. The complete 
search space can only be investigated for very small peptides and with increasing length 
quickly poses a problem which cannot be solved in a timely manner, if at all. Many 
algorithms have been developed trying to solve the de novo sequencing problem. Among 
them are naïve approaches, theory graph models, dynamic programming, probabilistic 
and combinatorial algorithms. 
In the following different de novo sequencing algorithms are introduced and a list of 
available tools is given for quick reference. Thereafter, the accuracy and available 
comparisons among popular de novo sequencing tools are assessed. Finally, guidelines 
for the usage of de novo sequencing tools and possible pitfalls are discussed followed by 
an outlook on the development of the field in the near future. 
The de novo Sequencing Problem 
The de novo sequencing problem is the need to assign an amino acid sequence to an 
MS/MS spectrum without the use of a sequence database or other additional information. 
De novo sequencing, of MS/MS spectra, is possible due to the fact that a peptide can be 
fragmented into predictable parts with current methods like collision-induced 
dissociation, CID, or collisionally activated dissociation, CAD, [10,11]. Other methods 
like electron transfer dissociation, ETD, [12] electron capture dissociation, ECD, [13], 
and many more achieve the same result.  
 
 Figure 1: Theoretically a peptide can fragment at any chemical bond in the molecule. Some 
frequently observed ions are named within the figure (ifi: internal fragment ion, scl: side chain loss). 
The names of the n-terminal ions are indicated on the left of the respective fragmentation border 
whereas the c-terminal portions are named on the right. A subscript indicates their position within 
the sequence in respect to their mass.  
 
Possible fragments have been named (Figure 1) for example a, b, and c for N-terminal 
fragments resulting from backbone cleavage of the amino acid sequence and x, y, and z 
for their complementing C-terminal fragments [14,15]. In the resulting MS/MS spectrum 
the ion types are not known a priori and they cannot easily be determined from basic 
principles for each peak. Thus the ion-types of the peaks in an MS/MS spectrum are 
unknown. Several fragments may further lead to similar mass to charge (m/z) ratios while 
neutral losses of H2O and NH3, for example, complicate the spectrum further. 
One of the challenges in de novo sequencing is thus assigning an ion type to each peak. 
Unfortunately, not all ions from the theoretical fragmentation are found in MS/MS 
spectra and typically, for low accuracy but abundantly available mass spectrometers, the 
low m/z (<300 Dalton, Da) and high m/z (>1800 Da) are not well populated with 
diagnostic peaks. Seidler and his colleagues reviewed the fragmentation process for 
several instrumentations and fragmentation methods in respect to de novo sequencing in 
more detail [16]. 
Any algorithm for de novo sequencing needs to assign an ion-type to the abundant peaks 
in an MS/MS spectrum and needs to establish consecutive ions of the same type, 
differing in the mass of an amino acid (subsequently referred to as ion ladders) which 
then can be assigned an amino acid sequence. This is possible since there should be peaks 
that differ in the mass of an amino acid which indicates that they are of the same ion-
type, forming an ion-ladder. However, due to the number of peaks many spurious 
assignments may be produced in this step. Furthermore, many peaks may be missed thus 
forming a complete ion-ladder to assign a sequence may not be possible. 
Derivatization of peptides to discern n-terminal from c-terminal fragments has been used 
successfully to facilitate de novo sequencing [17,18]. Keough and colleagues found that 
derivatization helped them to get long un-interrupted ion ladders [19]. Derivatization 
methods that simplify MS/MS spectra and fix the precursor charge to one of the 
fragments have been described [20,21]. Although derivatization may aid in de novo 
sequencing, such methods may not be widely adapted since they incur additional cost and 
labor. Thus, de novo sequencing algorithms need to be fast, reliable and shall not incur 
additional cost or experimental preparation steps. Instead of labeling the peptides natural 
isotopes can be used in a similar manner [22]. 
De novo sequencing can be solved in polynomial time when only n-terminal and c-
terminal fragments are considered. Xu and Ma showed that it becomes NP-complete (not 
solvable in linear time) when further fragment types are incorporated [23]. 
Another issue is the mass accuracy of mass spectra. Mass spectra with higher mass 
accuracy from high precision mass spectrometer lead to better de novo predictions [24-
27]. The fragmentation of precursor ions is not always successful, depending on the 
precursor abundance, how much of the precursor has been fragmented and with which 
energy. Therefore, it has been tried to establish the spectral quality prior to performing 
further analyses such as de novo sequencing [28,29]. Spectrum quality is here used in the 
sense of how well the precursor ion is fragmented into expected ions and how much their 
intensity is above potential random noise. It has been suggested that high-energy 
collisional dissociation (high-energy CID) spectra could aid in de novo sequencing [30] 
and it has been found that up to 80% of the high-energy CID spectra contain full or 
almost full ion ladders [31]. 
One problem, for both database search and de novo sequencing, which has not yet been 
properly addressed, is co-fragmentation of peptides with similar mass and retention time 
although there have been approaches in database searching [32]. 
De Novo Sequencing Algorithms 
A large number of de novo sequencing algorithms have been proposed and a non-
comprehensive list of algorithms, which provide an implementation, is presented in Table 
1. Another list of algorithms, which do not provide an implementation, can be found in 
Supplementary Table 1. Both tables contain an algorithm column which can be used to 
roughly group the de novo sequencing algorithms. Therefore, de novo sequencing tools 
using the same basic algorithm are discussed together. 
  
Table 1: Non comprehensive list of published de novo sequencing algorithms with available 
implementation. Information about availability, main algorithmic features, scoring function, and 
additional comments are provided. DP: dynamic programming, CO: commercial, OS: open source, 
EXE executable available, NA: listed source not available at time of writing. The table is sorted by 
decreasing citation count. 
Name Algorithm Scoring Comment Implementation Citation 
PEAKS Generation of 
10
5
 candidate 
sequences, 
DP 
Peak abundance, 
mass fit, fragment 
complementarity 
Commercial 
software, algorithm 
not fully disclosed 
http://www.bioin
for.com:9999/, 
CO 
[33] 
Lutefisk Spectrum 
graph 
Sum of b-ion 
probabilities during 
subseqeuncing 
Rescoring of 
prediction with 
several measures 
http://www.hairy
fatguy.com/lutefi
sk/, OS 
[34] 
PepNovo Spectrum 
graph 
Likelihood ratio 
hypothesis testing in 
respect to random 
model 
Only few learned 
models available 
http://cseweb.ucs
d.edu/groups/bio
informatics/soft
ware.html, OS 
[35] 
PepNovo Spectrum As Sherenga but High precision mass http://peptide.usc [24] 
graph additionally uses 
peak ranks and 
fragment 
dependencies 
spectrometric data 
needed 
d.edu, OS 
Unnamed Matrix 
spectrum 
graph 
Ion abundance ratio Tree searching to find 
all suboptimal 
solutions 
http://hto-
c.usc.edu:8000/
msms/menu/den
ovo.htm, NA 
[36] 
NovoHMM Hidden 
Markov 
model 
Bayesian posterior 
probabilities for 
amino acids 
Tested on 1252 
spectra and compared 
to other algorithms 
http://people.inf.
ethz.ch/befische/
proteomics/, 
EXE 
[37] 
SeqMS Spectrum 
graph 
Ion abundance, 
fragment 
complementarity 
 
Originally for HCD 
spectra later adapted 
for low energy CxD 
http://www.prote
in.osaka-
u.ac.jp/rcsfp/prof
iling/Seqms/Seq
MS.html, EXE 
[18,38] 
EigenMS Spectral 
graph 
partitioning 
Mass fit, ion 
abundance, 
probability to 
observe ion 
Usage of two graphs, http://sourceforg
e.net/projects/eig
enms/, OS 
[39] 
AuDeNs Spectrum 
graph, DP 
Internally calculated 
sum of peak 
relevance 
Assigns relevance to 
peaks during 
preprocessing 
http://www.ti.inf.
ethz.ch/pw/softw
are/audens/, EXE 
[40] 
MSNovo DP, 
mass  array 
spectrum 
representation 
Probabilistic 
distribution of mass 
tolerance 
LCQ/LTQ 
Charges 1-3 
http://msms.usc.e
du/s 
upplementary/ms
novo, NA 
[41] 
MAARIAN Exhausitive 
enumeration 
of peptide 
composition 
Sum of peak 
abundance matched 
by sequence 
MALDI, 
unimolecular 
decomposition, small 
example set, accuracy 
not assessed 
Available upon 
request, EXE 
[42] 
PFIA Exhaustive 
listing of all 
possible 
amino acid 
compositions 
- Ability to aid 
sequencing of cyclic 
peptides 
http://hodgkin.m
bu.iisc.ernet.in/~
pfia/, NA 
[43] 
Vonode Spectrum 
graph 
Based primarily on 
mass accuracy but 
in part also on 
fragment abundance 
Dependent on high 
mass accuracy, Also 
makes sequence tags 
http://compbio.or
nl.gov/Vonode, 
EXE 
[44] 
 
 
Naïve Approach 
One of the first approaches used to assign a sequence to a tandem MS spectrum is the 
brute force, or naïve, approach. In brief, all amino acid sequences approximately 
matching the measured precursor mass are generated and scored against the spectrum. 
The sequence with the highest score is then accepted as the correct solution [45,46]. With 
increasing precursor mass the number of possible sequences increase exponentially 
restricted only by the precursor mass accuracy which prohibits the use of this approach 
above a low mass cutoff [47]. This can be offset with increasing mass accuracy which 
may make this approach viable since the number of possible sequences is more restricted 
as shown in an approach termed composition based sequencing developed by Spengler in 
2004 [27]. See Zubarev and Mann for a disambiguation of mass accuracy and its proper 
usage [48]. Determining the sequence composition of candidates from a database, 
enumerating possible sequences, can also limit the number of sequences that need to be 
explored [42]. The commercial software, PEAKS, also uses exhaustive listing of 
sequences but restricts the amount of sequences to a subset of 10000. Unfortunately, their 
algorithm has not been fully disclosed [33]. The rescoring of candidate sequences has 
later been improved in PEAKS-RM [23].  
Instead of generating full sequences, subsequences can be determined by, for example 
extending short seed sequences determined directly from the MS/MS spectrum [49,50]. 
The DeNovo Explorer by Applied Biosystems, another example for subsequencing, first 
determines all subsequences and then transforms them into theoretical spectra and scores 
them against the experimental spectrum using percentage of matched peak intensity. 
More information is available on the web site of Applied Biosystems: 
http://www3.appliedbiosystems.com/cms/groups/psm_marketing/documents/generaldocu
ments/cms_040353.pdf. Often prefixes cannot be correctly determined and thus correct 
candidates are filtered [51]. Another alternative example for restricting the number of 
candidates determines sequence tags from the spectrum and builds a sequence database 
from these which is then scored against the spectrum [52]. 
Spectrum Graph 
A spectrum graph is the transformation of a peak list into a graph where each m/z value is 
represented by a node in the graph. Nodes are connected by edges if their m/z values 
differ by the mass of an amino acid. As a side effect, random noise in the spectrum is 
reduced since it should not create more additional edges than real fragment ions. 
Unexplained ion types, which may be considered noise by some algorithms, however, 
contribute with additional edges that complicate the spectrum graph. Figure 2 shows a 
spectrum graph where one forward ion-series and one reverse series are shown.  
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Figure 2: The figure shows the MS/MS spectrum sergei_digest_B_full_08.0628.0634.3.dta from the 
Keller dataset [53]. Ions of the singly charged b- and y-ion series are connected by edges with the 
amino acids as labels on the edges. Other node pairs that differ by the mass of an amino acid are not 
connected to avoid overcrowding of the figure. Pm indicates the precursor mass solid arrows show 
the b-ion series and dashed arrows show the y-ion series. Gray lines and amino acids are interpolated 
and have only partial evidence in the spectrum. The spectrum image was made with DtaViewer 
(http://www.biolnk.com, Allmer, unpublished). 
 
The nodes of the spectrum graph can be drawn on one line as it is done in Figure 2 where 
the value on the m/z axis is taken as the node center. The edges shown only represent the 
b- and y-ion series but many more edges can be drawn. Abundance can be encoded as an 
edge or node weight. In Figure 2 both series are internally uninterrupted and thus lead to 
a correct de novo prediction when the spectrum graph is traversed from either the first 
node or the last node. More information on how a spectrum graph can be traversed can be 
found in the following sections. Note that, the b-ion series gives the sequence in forward 
fashion whereas the y-ion series produces its reverse. In this case the graph can be drawn 
directed since the sequence is known but in general the resulting spectrum graph is 
undirected. Instead of only drawing edges if the mass of an amino acid fits between two 
nodes, the use of different edge types, connecting b-ions, y-ions, as well as 
interconnecting them, can add vital information to the spectrum graph [44]. Yan and 
colleagues took a similar approach and thus increased the information contained in their 
spectrum graph [54]. Bern and Goldberg have further constructed several graphs and 
have used graph partitioning [39]. A spectrum graph is used in further algorithms in 
Table 1 that have not been listed here individually [18,24,31,35,36,38,55-58].  
Dynamic Programming 
Dynamic programming is a technique that can be applied if a problem can be broken into 
smaller problems which are able to solve the larger problems, once solved themselves. 
Furthermore, the ability to build upon intermediate results is necessary for dynamic 
programming, ensuring no recalculations, which makes it especially suitable for finding 
optimal paths through a graph (e. g.: spectrum graph), although faster heuristics exist. 
Therefore, several algorithms make use of this technique for finding a path through the 
spectrum graph which may represent the peptide sequence of the precursor. Dynamic 
programming guarantees to find the optimal result but due to the complexity and not fully 
understood nature of MS/MS data the optimal sequence may not represent the correct 
sequence. In de novo sequencing, dynamic programming can be used to find the path 
potentially representing the correct peptide sequence in a spectrum graph [40,59-61]. A 
mass array encoding all possible peptide sequences can also be traversed by dynamic 
programming [41]. 
Sequence Optimization 
Instead of analyzing the MS/MS spectrum, it is also possible to optimize amino acid 
sequences to determine the one that best fits to the spectrum in respect to a scoring 
function. Genetic algorithms have been used for sequence optimization which is in 
essence quite similar to the naïve approach with the difference that not all possible amino 
acid sequences need to be generated. Instead, a small pool of amino acid sequences is 
generated and then optimized to best fit the MS/MS spectrum. This heuristic comes at the 
cost that finding the optimal result cannot be guaranteed. Moreover, in subsequent runs of 
the same algorithm with the same MS/MS spectrum different sequences may be reported 
as the best result. An early approach probably failed due to the fitness function which was 
not discriminative enough [62]. Heredia-Langner and colleagues, using a different fitness 
function, including shared peak count were more successful on the few spectra that they 
had at their disposal [63]. They compared the results with Lutefisk and reported to have 
similar sequence correctness.  
Other Algorithms 
Some approaches like the creation of spectrum graphs are shared among algorithms and 
are thus discussed in some more detail. Other algorithms like divide and conquer, for 
instance, are not in wide spread use. Zhang has used the divide and conquer algorithm for 
splitting the spectrum into successively smaller sub-spectra until they were solvable by 
the naïve approach and are then recursively re-integrated to solve the input spectrum [64]. 
The use of hidden Markov models, as an example for machine learning algorithms, has 
been used to tackle the de novo sequencing problem [37]. A pattern based algorithm has 
been introduced by Hines and colleagues [65]. Another recent approach seems to employ 
exhaustive listing of subsequences to aid manual interpretation of MS/MS spectra [43]. 
Most de novo sequencing algorithms consider all fragments to be singly charged but 
sequencing accuracy can be increased when using multiple charges as shown by Chong 
and colleagues [66].  
Integrative Approaches 
A tandem MS spectrum has limited information and several MS
2
 spectra may be used to 
add confidence to the information while MS/MS spectra generated with different 
fragmentation models can add information and add additional confidence at the same 
time.  
Bandeira and colleagues clustered MS/MS spectra and were thus able to derive more 
sequence information [67]. Another way of making use of the combination of multiple 
spectra is to collect MS
3
 spectra from selected fragment ions in MS/MS spectra and then 
combining the information to yield more meaningful data [68,69]. 
Zhang and Reilly used a combination of two MALDI fragmentation methods, post source 
decay, PSD, [70] and photodissociation [71]. They reported a sequence prediction 
success of about 91% and the ability to differentiate leucine and isoleucine, alas only on a 
very small dataset of 31 peptides [72]. Their approach makes use of x-ions to derive the 
peptide sequence and then uses y-, v-, and w-ions for further analysis. Datta and Bern 
combined the information contained in CID and ETD fragmentation spectra using an 
algorithm that not only combines the data but also separates n-terminal from c-terminal 
fragments [73]. They reported sequencing accuracies between 17% and 65%.  
Horn and colleagues discerned n-terminal and c-terminal ions using a combination of 
CID and electron capture dissociation, ECD, [13] spectra [74] while Savitsky and 
colleagues used the same fragmentation methods but integrated the information therein to 
yield a higher confidence for their predictions [26]. Zubarev and colleagues also 
investigated how ECD and CID fragmentation methods can be used synergistically and 
further included ETD fragmentation in their study [75]. Li and colleagues investigated 
how the combination of ECD and ETD spectra can aid in de novo sequencing [76].  
Algorithm Comparison 
In the absence of comprehensive datasets that cover the wide range of instrumentation 
and fragmentation possibilities as well as measurement settings it is not possible to 
proclaim one algorithm to be better than any other algorithm except for a particular 
instance of the problem [77]. One public dataset generated with an LCQ mass 
spectrometer from Thermo Electron published by Keller and colleagues [53], has been 
used in several studies to determine the quality of de novo prediction algorithms. It is 
highly desirable to have similar datasets for all types of mass spectrometers to enable a 
more complete picture about the qualities of de novo sequencing algorithms. 
Generally, datasets are created as a by product of other studies and are based on the 
identifications of database search programs which cannot guarantee correct identification; 
see recent reviews on database searching algorithms [78,79]. For benchmarking de novo 
sequencing algorithms this is not acceptable and all spectra should be prepared from 
purified peptides and synthetic peptides to ensure correct sequence assignment.  
Accuracy Definitions 
In order to make de novo predictions comparable, an accuracy measure has to be selected. 
Since an accuracy measure to evaluate de novo sequencing algorithms has not been 
agreed upon, different studies use different quality measures. 
Xu and Ma used two measures, 1) the number of correctly predicted amino acids divided 
by the number of amino acids in the real peptide, and 2) the number of correctly 
predicted amino acids divided by the number of amino acids in the prediction [23]. It also 
needs to be agreed upon when an amino acid is said to be correctly predicted. Xu and Ma 
state that the amino acid must be at the same mass position in the prediction as in the 
correct peptide [23]. But other definitions like the one by Pitzer and colleagues who use 
the notion of longest common subsequence to evaluate the accuracy of sequence 
predictions [80], may equally well define similarity. Another similarity measure was 
given by Pevtsov and colleagues who extended the edit distance algorithm with modifiers 
explicitly modeling expectable problems in de novo predictions [81]. They used relative 
sequence distance as their accuracy measure. Mo and colleagues define the prediction 
accuracy as the ratio of correctly predicted amino acids over total amino acids in the 
predicted peptide (similar to Xu and Ma) and recall as the number of correctly predicted 
residues over the total number of residues in the correct peptide [41]. Bringans and 
colleagues use the former method for their accuracy assessment of de novo sequencing 
algorithms [82]. An all or nothing score, either the sequence is correctly predicted and the 
best prediction of the algorithm, or otherwise is false, may be too harsh a criterion with 
current instrumentation and de novo sequencing algorithms. Nonetheless, it is one of the 
scores employed in a study by DiMaggio and Floudas [55]. They further report the 
prediction accuracy in respect to sequence distance similar to but not exactly like Pevtsov 
and colleagues. They further incorporate percentage of matched amino acid residues and 
correctly predicted subsequences in their study. 
For the future, it would be desirable to agree upon a number of accuracy measures that 
need to be reported in a study comparing different de novo sequencing algorithms. 
Comparisons of Multiple Algorithms 
Currently, there is a trend that each newly developed de novo sequencing algorithm 
compares its results with a selection of other algorithms. Unfortunately, independent 
researchers rarely assess the quality of de novo sequencing algorithms which would 
remove possible biases. In a crude assessment we checked the overlap of sequence 
assignments of several de novo sequencing algorithms with database search results. 
Spectra that had agreeing sequence assignments by Sequest, OMSSA, and X!Tandem, 
were used for this comparison. The outcome was most disappointing for the de novo 
sequencing algorithms which is likely due to the usage of spectra with low mass 
accruracy from an LCQ mass spectrometer (Boz and Allmer, unpublished). 
Xu and Ma used three small datasets to compare PEAKS, their extension to PEAKS 
(PEAKS-RM), and PepNovo and concluded that their new method was better than the 
other methods, with them performing similarly on the datasets that they investigated. For 
their dataset they achieved an accuracy between 6 to 7 out of 10 amino acids [23]. Often, 
as also in this case, de novo sequencing algorithms are tested on rather small datasets 
comprised of high quality spectra [80]. While Pitzer and colleagues improved on this and 
incorporated spectra from several instruments, they still only used a subset of available 
instrumentation and algorithms. They compared Lutefisk and PepNovo and observed that 
PepNovo is more successful on ion trap and MALDI data whereas Lutefisk is more 
successful on QTOF data. From their data it can also be derived that, if an average 
peptide length of 10 is assumed, the correct prediction of more than 6 out of 10 amino 
acids is a rare event. Pevtsov and colleagues compared a larger number of different de 
novo sequencing algorithms, namely Audens, Lutefisk, NovoHMM, PepNovo, and 
PEAKS [81]. Their dataset was somewhat smaller than the one of Pitzer and colleagues 
but one ingredient, the measurements of Keller and colleagues are present in both studies 
as well as in a study by Mo et al. [41]. Pitzer and colleagues found that QStar data, with 
maximum of 50% correct sequences, lead to better predictions for all algorithms as 
compared to LCQ data, with a maximum of 18% correctly sequenced spectra. They 
found that for QStar data PEAKS performs better than Lutefisk and PepNovo, which in 
turn perform better than Audens and NovoHMM. For LCQ data NovoHMM performed 
best with PepNovo and PEAKS close behind, followed by Lutefisk and then Audens. Mo 
and colleagues focused on LCQ and LTQ data and reported that their algorithm performs 
better than PepNovo and NovoHMM with an accuracy between 12% and 50% depending 
on the dataset. Looking at the reported recall values MSNovo, their algorithm, does not 
significantly outperform the other tools and is at times less precise than NovoHMM 
which could put MSNovo on a level with NovoHMM in the Pevtsov study for LCQ data. 
Bringans and colleagues found that for a small data set of 4800 MALDI TOF/TOF 
spectra PEAKS was, with 66%, slightly more accurate than PepNovo and both were more 
than 10% more accurate than Applied Biosystem’s DeNovoExplorer [82]. For QTRAP 
data PepNovo was slightly better than PEAKS and achieved an accuracy of 65%. Both 
were significantly better than DeNovoExplorer which only predicted 27% of the residues 
correctly. DiMaggio and Floudas compared the performance of several de novo 
sequencing algorithms on a very small number of spectra (38) from a QTOF instrument 
[33] and found that their algorithm PILOT performed best with PEAKS Online, 
EigenMS, Lutefisk, and LutefiskXP being decreasingly less accurate in terms of fully 
correct sequence prediction [55]. For ion trap data (36 spectra) they found that PILOT 
performed best with NovoHMM, PepNovo, EigenMS and PEAKS Online, and Lutefisk 
XP being decreasingly less accurate. 
The studies by Bringans and colleagues, Pevtsov and colleagues, as well as Pitzer and 
colleagues were independent assessments of prediction accuracy, whereas the other 
studies mentioned above were a selection of studies that while introducing a new 
algorithm compare it with existing algorithms. 
Determining Sequence Tags 
As shown in the previous section, it is difficult to determine full length sequences from 
MS/MS spectra. In order to map the spectra to their peptide sequence, or several spectra 
to a protein sequence, it is not absolutely necessary to determine full length de novo 
sequences. Short sub sequences, so called sequence tags, can be successfully mapped to 
protein sequences if a sequence database exists. This can be viewed as a special case of 
de novo sequencing where the tags don’t have to be full length sequences. Or, vice versa, 
de novo sequencing could be a special case of determining sequence tags where the tag 
happens to be the full length sequence. Determining short sequence tags with high 
confidence enables the retrieval of peptide sequences from a database that match to this 
tag; a strategy often referred to as filtration. The problem is whether a tag is forward, 
derived from an n-terminal ion series, or reverse, derived from a c-terminal ion series. 
Programs that derive sequence tags from MS/MS spectra are listed in Table 2.  
 
Table 2: A non comprehensive list of algorithms determining a sub sequence (sequence tag) from 
MS/MS spectra. OS: open source, EXE executable available, NA: listed source not available at time 
of writing. The table is sorted by decreasing citation count. 
Name Comment Implementation Citation 
GutenTag Determines short sequences from MS/MS, 
ranked by presence of expected ions 
http://fields.scripps.edu, 
EXE 
[83] 
OpenSea Treats sequence database and mass spectrum 
as a sequence of masses 
http://libopensea.com/, ? [84] 
PepNovoTag Uses PepNovo for tag generation and employs 
a probabilistic approach for tag scoring 
http://proteomics.ucsd.edu/
, NA 
[85] 
DirecTag Evaluates tags in respect to peak intensity, m/z 
fit, and fragment ion complementarity 
http://fenchurch.mc.vander
bilt.edu/bumbershoot/direc
tag/, OS 
[86] 
Spectral 
Profiles 
Creates gapped sequence tags and spectral 
profiles from MS/MS spectra 
NA [87] 
 
Short tags usually map to several peptides in a database so that a combinatorial problem 
needs to be solved. A number of algorithms have been developed to solve this problem 
(see Table 3). The generation of sequence tags is often a prerequisite for the algorithms 
listed in Table 3. GutenTag for instance assembles tags of a user specified length from 
MS/MS spectra and then matches the 25 best scoring tags to a sequence database [83]. 
Tabb and colleagues later applied more rigorous statistical models to the tag generation in 
their DirectTag algorithm [86]. Frank and colleagues emphasize the importance of tags to 
be on a valid global de novo path and add a probabilistic filtering step to the tag creation 
[85]. Instead of using sequence tags Searle and colleagues introduced the notion of mass 
tags treating both database and tag as a sequence of masses [84]. 
 
Table 3: A non comprehensive list of algorithms that map sequence tags or full de novo sequences 
derived from mass spectra to a sequence database. OS: open source, EXE executable available, NA: 
listed source not available at time of writing, OV: online version, AR available upon request. The 
table is sorted by decreasing citation count. 
Name Algorithm Comments Implementation Citation 
MSBlast Accounts for MS specific 
problems and maps tags to 
database 
Uses WU-BLAST2 
for homology 
searching 
http://genetics.bwh
.harvard.edu/msbla
st, OV 
[88] 
Inspect Uses spectrum graph for tag 
generation and trie for 
database search 
Uses filtering of the 
database to find PTMs 
http://proteomics.u
csd.edu, OS 
[89] 
FASTS Integrates the combined 
mapping of multiple short 
sequences to a sequence 
database 
Based on FASTA, 
comes in two flavors, 
FASTS and FASTF 
http://fasta.bioch.vi
rginia.edu/fasta_w
ww2/fasta_list2.sht
ml, OS 
[90] 
CIDentify Uses complete de novo 
sequences with mass gaps  
Allows for common 
errors in the de novo 
prediction 
http://faculty.virgin
ia.edu/wrpearson/f
asta/OLD/CIDentif
y/, EXE 
[91] 
ByOnic Determines likely b- and y-
ions for lookup in the 
subsequent database search 
Tests showed that it 
was more sensitive 
than database search 
algorithms 
NA [92] 
GenomicPe Maps de novo predictions Allows analysis of http://www.allmer. [93,94] 
ptideFinder error tolerantly to a genomic 
database 
intron exon borders 
and can find 
alternative splicing 
events 
de/software/gpf/, 
AR 
MS-
Dictionary 
Matches all plausible de novo 
predictions to the sequence 
database 
They report increased 
sensitivity in 
comparison to 
X!Tandem 
http://proteomics.u
csd.edu, AR 
[95] 
IggyPep Maps de novo predictions 
error tolerantly to an indexed 
genomic database 
Unclear how it 
improved upon 
existing methods 
http://www.iggype
p.org, OV 
[96] 
Spider Accounts for errors in 
sequence tags 
Uses editing 
operations to align 
sequences 
http://bif.csd.uwo.c
a/spider, NA 
[97] 
 
Shevchenko and colleagues used PredictSequence for generation of sequence tags and 
used WU-BLAST2 for matching the sequence tags, while accounting for typical MS 
problems and integrating the resulting database matches [88]. 
Mackey and colleagues build on the FASTA heuristic and added combinatorics to 
integrate multiple short hits and also changed FASTA’s scoring scheme to alignment 
probability [90]. A similar approach has been taken by Johnson and Taylor who have 
used CIDentify, a version of FASTA predating Mackey’s improvement [91]. Lu and 
Chen implemented a search of a sequence database, indexed using a suffix tree, against a 
spectrum graph [98]. The GenomicPeptideFinder (GPF) uses de novo predictions and 
maps them error tolerantly to the six frame translation of a genomic database. It has been 
used to investigate Chlamydomonas reinhardtii and significantly increased the number of 
detected peptides as well as suggested new splicing events [93,94]. RAId [99] and MS-
Dictionary [87] also use multiple de novo sequences to map them to the six frame 
translation of a genomic database. IggyPep uses an indexed genomic database to map de 
novo sequences or sequence tags. It has been used on the genome of Sea Urchin and 
helped to find additional neuropetides [8]. It is, however, unclear how IggyPep improves 
upon GPF, RAId, MSBlast and other methods. Inspect uses sequence tags to filter a 
sequence database to derive candidates that may contain PTMs [89]. 
Instead of using sequence tags, or gapped tags, [87] ByOnic uses lookup peaks to filter 
sequence databases [92]. 
Data Integration 
De novo sequencing provides the complete amino acid sequence of an MS/MS spectrum 
whereas sequence tags only provide short but positioned subsequences. Both can be used 
for error tolerant database search while de novo sequence predictions can also be used 
standalone. Integrating information from de novo sequencing, database search and 
additional resources can increase the confidence in each protein identification [100].  
OVNIp is an application that has recently been published. It allows the exploitation of de 
novo sequences, in tandem with database search programs, to increase the confidence in 
protein identification [101]. In the future, it would be good to have similar tools which 
from de novo peptide predictions create de novo protein predictions and compare these 
with known protein sequences. 
Application 
De novo sequencing has recently gained a lot of attention and numerous studies, making 
use of it, have been published in the last three years. Due to the low accuracy of de novo 
predictions, it is mostly used in tandem with database search algorithms. In this way, 
adding confidence to peptide and protein identification, aiding in enlarging the number of 
MS/MS spectra that can be assigned a sequence, or suggesting MS/MS spectra that could 
be derived from a peptide precursor with a PTM. 
Although more than 60% of amino acid residues can be correctly predicted by some 
algorithms under specific circumstances, only 30% of the peptides are correctly predicted 
[82]. The accurate prediction of full-length sequences remains challenging [31]. This is 
quite limiting when working with unsequenced species or sequences that are not expected 
to be in any database. This is inline with the view of Zubarev and colleagues, who state 
that de novo sequencing is the answer to interpretation of mass spectra but point out that 
adequate accuracy can only be achieved with highly accurate mass spectrometers, using a 
combination of multiple fragmentation methods [75]. 
Regardless of the limitations, de novo sequencing has been used, in high-throughput 
studies and lead to findings that would not have been possible otherwise [102,103]. The 
current limitations of sequencing peptides and proteins de novo is very well documented 
in a study that sequenced a beta-defensin of reptilian origin. The authors faced a 
multitude of problems and resorted to the use of a combination of multiple mass 
spectrometers, multiple fragmentation methods and different derivatization methods, as 
well as getting aid from Edman degradation [104], until they were successful [105]. 
Another study, sequencing a hormone, faced similar problems and came to similar 
conclusions but further added top-down sequencing while not employing Edman 
degradation [106]. 
Outlook 
De novo sequencing may be useful in assigning meaning to unidentified, high quality 
mass spectra, when it is used as a part of an identification pipeline, for example extending 
the one built by Ning and colleagues [107]. Such multi-pass approaches, in contrast to 
multi-search analyses, reduce the number of false negatives while not significantly 
increasing the overall runtime [108]. Therefore it can be expected that de novo 
sequencing will, increasingly, find its way into computational pipelines for MS data 
analysis, as exemplified in a study by Junqueira and colleagues [109], in the near future. 
It has long been recognized in proteomics that standards and standard datasets need to be 
available for benchmarking of the current state of the art and new methods [110]. This is 
not different in de novo sequencing and it seems essential that current tools be properly 
evaluated under a wide range of practical conditions. Although amenable, it is unlikely 
that this will happen within the near future due to constantly changing instrumentation 
and fragmentation methods. 
In general de novo sequencing algorithms are easier adaptable to include the detection of 
post translational modifications than database search algorithms which quickly have to 
face databases of insurmountable size when multiple PTMs are considered. Although 
many de novo sequencing algorithms include the ability to search for static, variable, 
multiple, or a combination of PTMs, due to the infancy of the de novo prediction 
algorithms for PTM detection, they have not been discussed in this review. In the near 
future more tools will be developed that either predict PTMs directly from MS/MS data 
or use multi-pass analysis on a collection of spectra to assign PTMs [111-113]. With 
these methods or a combination of methods, proper assignment of PTMs will become 
possible.  
Expert commentary 
One of the central dogmas in biology, one gene leading to one transcript, has been proven 
false and the real problem seems quite complicated rather than straight forward. This 
includes alternative splicing, alternative start and stop sites and other means that lead to 
unexpected proteins. Mass spectrometry has become predominant for many areas of in 
proteomics. For protein identification database search is being used but this strategy fails 
when any alternative transcripts have not been annotated and are thus not available in 
sequence databases. This problem is elevated since most proteins have not been 
sequenced on the protein level but are mere predictions with large associated errors. 
Mapping EST sequences can help in this case but currently only for abundant transcripts. 
An additional problem inherent in database search algorithms is that the precursor mass 
needs to fit to the sequence within certain bounds which makes post translational 
modifications a difficult problem.  
Therefore, only de novo sequencing algorithms can ultimately be used to sequence 
proteins. This currently comes with the cost that de novo sequencing algorithms are not 
precise enough to provide high confidence in their sequencing results. This may in one 
part be due to the fact that more effort has been put into the development and assessment 
of database search algorithms and in another part be due to the need for high quality 
spectra when performing de novo sequencing. Another point is the large abundance of 
different instrumentation including various fragmentation methods. Peptide 
fragmentation is still under investigation for even established methods and has not been 
fully understood. Fragmentation pathways are the basis for many de novo sequencing 
algorithm and if they were clearly defined the prediction quality would increase 
considerably. At this point it is thus difficult for a user to find the best suited de novo 
sequencing algorithm for their instrumentation. 
It is, however, possible to amend database search results with de novo sequencing results 
and the synthesis of this information can already increase the detectable number of 
proteins and the confidence in their identification.  
Five-year view 
Currently, the number of different instruments and fragmentation methods is constantly 
increasing and this may not stop in the near future making it possible for developers to 
present ever more niche de novo sequencing algorithms targeted to one particular mass 
spectrometer. This does not help the consolidation of current de novo sequencing 
methods and also complicates the independent comparison of their performance which is 
seen by the fact that only few independent comparisons have been made but not within 
the last 3 years.  
A trend, further complicating the matter, to combine spectra from multiple fragmentation 
procedures can be seen in the literature but ultimately it will be necessary to perform 
sequencing using one mass spectrometer with a single fragmentation method to enable 
high throughput analyses and thus these studies may be abandoned in the future. 
Post translational modifications (PTMs) pose a great difficulty to mass spectrometry-
based proteomics if the PTMs are not anticipated. Some studies claim to accommodate 
for even unexpected PTMs and in the near future a focus of the field will be to turn this 
claim into reality for a selected number of high end mass spectrometers. Within the next 
three years some algorithms will be able to sequence short peptides containing one 
unexpected PTM successfully.  
In general, the support for low cost mass spectrometers is decreasing and the focus will 
be on new high end machines which offer a greater success rate for de novo sequencing 
algorithms and it is unlikely that this trend will reverse in the future. 
Within the next five years fragmentation pathways will not be fully understood and thus 
algorithms based on this expert knowledge will still be hampered by unexplained peaks 
within MS/MS spectra. 
Within the next five years the number of comparative studies may increase again 
whenever competing de novo sequencing algorithms are proposed for the same mass 
spectrometer and fragmentation method combination. There will however be very few 
studies comparing de novo sequencing results across platforms a trend which will 
continue until new mass spectrometers are only marginally better than their predecessors.  
Key issues 
 Mass spectrometry is the key tool for performing proteomics. 
 Database search algorithms, and those using sequence tagging, have inherent 
problems that prevent them from identifying all possible amino acid sequences. 
 De novo sequencing is similar to sequence tagging but provides a full length 
amino acid sequence; it is dissimilar from it and database search algorithms in 
that it is independent of any additional information than contained in an MS/MS 
spectrum. 
 De novo amino acid sequencing from MS/MS spectra offers the possibility to 
sequence any peptide or protein precursor. 
 Many de novo sequencing approaches have been proposed using a wide variety of 
algorithms to solve the de novo sequencing problem. 
 It is difficult to compare existing algorithms since they are often targeted to  
specific experimental setups and since no quality measures have been agreed 
upon in the field. 
 The accuracy of de novo predictions is not yet good enough to solely rely on them 
for the sequencing of a proteome. 
 Although it is possible, for most existing algorithms, to include post translational 
modifications this is not discussed in this review due to the infancy of the field in 
this respect. 
 Integrative approaches using a combination of methods are able to elevate this 
problem for already sequenced organisms; thus being able to combine database, 
sequence tagging, de novo sequencing and other information. 
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